10,410 Shares in Revolution Medicines, Inc. $RVMD Bought by Aristotle Atlantic Partners LLC

Aristotle Atlantic Partners LLC purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,410 shares of the company’s stock, valued at approximately $829,000.

Other institutional investors have also bought and sold shares of the company. Global Retirement Partners LLC grew its holdings in Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after buying an additional 361 shares in the last quarter. Indiana Trust & Investment Management Co purchased a new position in shares of Revolution Medicines in the 4th quarter worth approximately $32,000. Torren Management LLC purchased a new position in shares of Revolution Medicines in the 4th quarter worth approximately $33,000. Arax Advisory Partners purchased a new position in shares of Revolution Medicines in the 4th quarter worth approximately $38,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Revolution Medicines in the 4th quarter worth approximately $40,000. Institutional investors own 94.34% of the company’s stock.

Insiders Place Their Bets

In related news, COO Margaret A. Horn sold 60,400 shares of Revolution Medicines stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $160.17, for a total value of $9,674,268.00. Following the completion of the sale, the chief operating officer owned 158,222 shares of the company’s stock, valued at approximately $25,342,417.74. This trade represents a 27.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark A. Goldsmith sold 120,000 shares of Revolution Medicines stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the sale, the insider directly owned 276,698 shares of the company’s stock, valued at approximately $41,529,602.82. This trade represents a 30.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 210,000 shares of company stock worth $32,424,620 in the last ninety days. Insiders own 7.60% of the company’s stock.

Analyst Ratings Changes

RVMD has been the topic of a number of research analyst reports. Jefferies Financial Group initiated coverage on Revolution Medicines in a research note on Monday, March 16th. They issued a “buy” rating on the stock. UBS Group initiated coverage on Revolution Medicines in a research note on Friday, February 27th. They issued a “buy” rating on the stock. Guggenheim boosted their target price on Revolution Medicines to $205.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Evercore restated an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday, April 14th. Finally, Stifel Nicolaus restated a “buy” rating on shares of Revolution Medicines in a research note on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $123.72.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $157.77 on Thursday. The firm has a market cap of $33.54 billion, a price-to-earnings ratio of -22.32 and a beta of 1.40. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.80 and a current ratio of 6.80. Revolution Medicines, Inc. has a 52 week low of $34.00 and a 52 week high of $166.50. The firm’s 50-day simple moving average is $144.38 and its two-hundred day simple moving average is $112.39.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period last year, the company earned ($1.13) EPS. As a group, equities analysts forecast that Revolution Medicines, Inc. will post -7.94 earnings per share for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.